Shu, C. A., Goto, K., Ohe, Y., Besse, B., Park, K., Wang, Y., Griesinger, F., Yang, J. C.-H., Felip, E., Sanborn, R. E., Caro, R. B., Bauml, J. M., Chen, J., Fennema, E., Mahoney, J., Trani, L., Knoblauch, R. E., Thayu, M., & Cho, B. C. (2021). 1193MO Amivantamab plus lazertinib in post-osimertinib, post-platinum chemotherapy EGFR-mutant non-small cell lung cancer (NSCLC): Preliminary results from CHRYSALIS-2. Annals of Oncology, 32, S952–S953. https://doi.org/10.1016/j.annonc.2021.08.1798